Accès ouvert
2026
preprint
OpenAlex
Boris Noyvert, A Mesut Erzurumluoglu, Dmitriy Drichel, Steffen Omland et autres
Advancements in long-read sequencing technology have accelerated the study of large structural variants (SVs). We created a curated, publicly available, multi-ancestry SV imputation panel by long-read sequencing 888 samples from the 1000 Genomes Project. This high-quality panel was used to impute SVs …
us, au, gb, de, in
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Boris Noyvert, Abdullah Mesut Erzurumluoglu, Dmitriy Drichel, Steffen Omland et autres
Advancements in long-read sequencing technology have accelerated the study of large structural variants (SVs). We created a curated, publicly available, multi-ancestry SV imputation panel by long-read sequencing 888 samples from the 1000 Genomes Project. This high-quality panel was used to impute SVs …
us, au, gb, de, in
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Boris Noyvert, Abdullah Mesut Erzurumluoglu, Dmitriy Drichel, Steffen Omland et autres
Abstract Advancements in long-read sequencing technology have accelerated the study of large structural variants (SVs). We created a curated, publicly available, multi-ancestry SV imputation panel by long-read sequencing 888 samples from the 1000 Genomes Project. This high-quality panel was used to impute …
us, au, gb, de, in
(code pays fourni par la source)
Accès ouvert
2023
preprint
OpenAlex
Boris Noyvert, Abdullah Mesut Erzurumluoglu, Dmitriy Drichel, Steffen Omland et autres
Abstract Advancements in long-read sequencing technology have accelerated the study of large structural variants (SVs). We created a curated, publicly available, multi-ancestry SV imputation panel by long-read sequencing 888 samples from the 1000 Genomes Project. This high-quality panel was used to impute …
de, gb, us
(code pays fourni par la source)
Accès ouvert
2023
other
OpenAlex
Laetitia Devy, Lili Huang, Laurent Naa, Niranjan Yanamandra et autres
Abstract Inhibition of specific matrix metalloproteinases (MMP) is an attractive noncytotoxic approach to cancer therapy. MMP-14, a membrane-bound zinc endopeptidase, has been proposed to play a central role in tumor growth, invasion, and neovascularization. Besides cleaving matrix proteins, MMP-14 activates proMMP-2 leading …
us, ca
(code pays fourni par la source)
Accès ouvert
2023
supplementary-materials
OpenAlex
Laetitia Devy, Lili Huang, Laurent Naa, Niranjan Yanamandra et autres
Supplementary Methods and Materials from Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis
Accès ouvert
2023
supplementary-materials
OpenAlex
Laetitia Devy, Lili Huang, Laurent Naa, Niranjan Yanamandra et autres
Supplementary Tables1-2 from Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis
Accès ouvert
2023
supplementary-materials
OpenAlex
Laetitia Devy, Lili Huang, Laurent Naa, Niranjan Yanamandra et autres
Supplementary Tables1-2 from Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis
Accès ouvert
2023
supplementary-materials
OpenAlex
Laetitia Devy, Lili Huang, Laurent Naa, Niranjan Yanamandra et autres
Supplementary Methods and Materials from Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis
Accès ouvert
2023
other
OpenAlex
Laetitia Devy, Lili Huang, Laurent Naa, Niranjan Yanamandra et autres
Abstract Inhibition of specific matrix metalloproteinases (MMP) is an attractive noncytotoxic approach to cancer therapy. MMP-14, a membrane-bound zinc endopeptidase, has been proposed to play a central role in tumor growth, invasion, and neovascularization. Besides cleaving matrix proteins, MMP-14 activates proMMP-2 leading …
Accès ouvert
2022
article
OpenAlex
Andreas Gollner, Markus Köster, Paul L. Nicklin, Thomas Trieselmann et autres
at, cn, de, fr, es, gb, ca, us, in
(code pays fourni par la source)
Accès ouvert
2015
article
OpenAlex
Andrew E. Nixon, Jie Chen, Daniel J. Sexton, Arumugam Muruganandam et autres
The therapeutic management of antibody-mediated autoimmune disease typically involves immunosuppressant and immunomodulatory strategies. However, perturbing the fundamental role of the neonatal Fc receptor (FcRn) in salvaging IgG from lysosomal degradation provides a novel approach - depleting the body of pathogenic immunoglobulin by …
us
(code pays fourni par la source)